Entera Bio Ltd. (ENTX) · Nov 6, 2026 · Earnings
Miss — EPS -$0.11 vs approximately -$0.065 consensus
Entera Bio’s Q3 earnings missed consensus, but the company says EB613 Phase 3 startup remains on track and funded through 2030.
Entera is a clinical-stage oral-peptide biotech moving its lead osteoporosis drug, EB613, from Phase 2 into a funded registrational Phase 3 program. The FDA has already aligned with a roughly 750-patient Phase 3 design and a 12-month total-hip BMD endpoint, while the July financing was intended to fund the program through an anticipated NDA submission.
The operating story is still on schedule. Management repeated that first-site activation for EB613 is expected in late 2026, which is consistent with the previously disclosed launch plan rather than a new acceleration or delay. 〔0〕
The quarter missed the narrow earnings benchmark, but the miss is low quality. Net loss was $0.11 per share versus a published consensus of approximately $0.065 per share, while the company attributed much of the deterioration to a $7.5 million non-cash fair-value remeasurement of pre-funded warrants. The miss therefore says more about warrant accounting than about clinical execution.
| Figure | Q3 2026 | Q3 2025 | Consensus |
|---|---|---|---|
| EPS (Financial Results) | -$0.11 | -$0.07 | -$0.065 |
| R&D expense (R&D Expenses) | $4.9M | $1.6M | |
| Cash and equivalents (Cash and Cash Equivalents) | $265.9M |
The financing has materially reduced near-term funding risk. Entera says its cash resources should fund the planned EB613 Phase 3 program through topline results and an anticipated NDA submission, with operations supported into 2030. That is important for a company entering an expensive late-stage trial, although it was already largely established by the July $275 million private placement. 〔1〕
The main new spending is consistent with execution, not deterioration. R&D expense rose to $4.9 million from $1.6 million as Phase 3 startup and OPKO collaboration activity began, confirming that Entera is shifting from preparation toward clinical execution.
Bottom line: This is an earnings miss, but the core EB613 launch and funding story remains intact. The filing is mildly negative versus the earnings bar, not a setback to the company’s late-stage clinical plan.
First EB613 Phase 3 site activation, late 2026
A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.
A buy-side analyst on every ticker — the whole market decoded the second it moves, before it's a headline. Free gives you a taste. Pro takes the cap off and opens the full read on every company.
by Signing in NOW, claim your FREE 14-day Pro trial!